1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,480 | 8,640 | 26.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | 183 | Xetra Newsboard | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| 04.06. | Bioventus Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Transcript: Bioventus Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 29.05. | Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 21.05. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.05. | Bioventus outlines 2026 adjusted EPS of $0.75-$0.79 while reaffirming $600M-$610M revenue | 1 | Seeking Alpha | ||
| 06.05. | Bioventus nach starkem Quartal: Gewinnprognose für 2026 angehoben | 1 | Investing.com Deutsch | ||
| BIOVENTUS Aktie jetzt für 0€ handeln | |||||
| 06.05. | Bioventus Q1 2026 slides: earnings beat drives guidance raise | 1 | Investing.com | ||
| 06.05. | Bioventus Non-GAAP EPS of $0.15 beats by $0.08, revenue of $132.1M beats by $2.2M | 2 | Seeking Alpha | ||
| 06.05. | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | 217 | GlobeNewswire (Europe) | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen | |
| 06.05. | Bioventus Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.05. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.04. | Bioventus, Inc.: Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026 | 4 | GlobeNewswire (USA) | ||
| 06.03. | Craig-Hallum hebt Kursziel für Bioventus nach übertroffener Prognose an | 1 | Investing.com Deutsch | ||
| 06.03. | Craig-Hallum raises Bioventus stock price target on guidance beat | 2 | Investing.com | ||
| 05.03. | Bioventus outlines $600M-$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics | 1 | Seeking Alpha | ||
| 05.03. | Bioventus-Aktie springt nach übertroffenen Quartalserwartungen um 7,6 % | - | Investing.com Deutsch | ||
| 05.03. | Bioventus Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 05.03. | Bioventus Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Bioventus übertrifft Q4-Prognosen und gibt Ausblick für 2026 | 1 | Investing.com Deutsch |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,330 | +0,43 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,220 | +4,27 % | Innovation in der Forschung: Chancen bei Vertex Pharmaceuticals, BioNxt Solutions und BioNTech! | In Sozialen Medien findet man allerlei negative Kommentare und Memes zum Pfizer Konzern. Eine sehr populäre Behauptung lautet, dass der von deutschen Einwanderern in New York gegründete Konzern (Karl... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,820 | +0,78 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,000 | +0,25 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 70,92 | +2,13 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) | REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and... ► Artikel lesen | |
| ATAIBECKLEY | 4,400 | -4,76 % | AtaiBeckley to join Russell 2000, 3000 indexes | ||
| ALDEYRA | 1,510 | -6,79 % | Aldeyra appoints Darlene Deptula-Hicks to board of directors | ||
| ADAPTIVE BIOTECHNOLOGIES | 18,180 | -1,25 % | Adaptive Biotechnologies Corp - 8-K, Current Report | ||
| ABCELLERA BIOLOGICS | 6,400 | -1,23 % | ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains? | ||
| BIOMERIEUX | 70,75 | 0,00 % | BioMérieux Aktie steigt nach FDA Antrag für Vaginitis Panel | ||
| AC IMMUNE | 2,215 | -1,34 % | AC Immune SA: AC Immune First Quarter 2026 Financial and Corporate Updates | AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers... ► Artikel lesen | |
| 10X GENOMICS | 31,280 | -3,01 % | 10x Genomics, Inc.: 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group | Acquisition Expands 10x Genomics' Capabilities in Proteomics
PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science... ► Artikel lesen | |
| AGIOS | 33,200 | 0,00 % | TD Cowen empfiehlt Biotech-Aktie: Agios überzeugt mit starkem Thalassämie-Geschäft | ||
| BIOXCEL THERAPEUTICS | 1,095 | -3,95 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| AGENUS | 2,520 | -5,26 % | Agenus Inc.: Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 | Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b study Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year... ► Artikel lesen |
Das Unternehmen BIOVENTUS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,23 % bei einem Aktienkurs von 8,560 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVENTUS INC finden Sie auf Wallstreet Online.